Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma
BACKGROUND: A single, high priming dose of tremelimumab (anti-cytotoxic T lymphocyte–associated antigen 4) plus durvalumab (anti–programmed cell death ligand-1), an infusion reg...